Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Neurodegenerative Disease, Hereditary

Tundra lists 3 Neurodegenerative Disease, Hereditary clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT06672237

A Phase 3 Study of NTLA-2001 in ATTRv-PN

This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.

Gender: All

Ages: 18 Years - 85 Years

Updated: 2025-11-26

Neuromuscular Disease
Neuromuscular Diseases (NMD)
Neurodegenerative Disease
+17
RECRUITING

NCT05518617

Molecular and Functional Imaging in Monogenic PD.

In this study, the investigators aim to find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of PD symptoms.

Gender: All

Ages: 25 Years - 80 Years

Updated: 2025-10-07

1 state

Parkinson Disease
Nervous System Disorder
Neurodegenerative Diseases
+2
NOT YET RECRUITING

NCT06177028

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

This is a randomized, double-blind, placebo-controlled, parallel group study. The use of placebo is appropriate to minimize bias related to treatment expectations of the subject, study partner, and site investigator, as well as to changes in the relationship between the subject and study partner that might occur with the initiation of treatment and expectation of improvement in motor symptoms or cognition. Changes in subject/study partner interactions can impact subject mood and might introduce biases that cannot be quantified. The double-blind use of placebo will also prevent bias in the clinical and scientific assessments.

Gender: All

Ages: 50 Years - 90 Years

Updated: 2025-05-18

Cognitive Impairment, Mild
Cognitive Dysfunction
Amyloid Plaque
+2